Hyperplasia of the mammary glands(HMG)is a noninflammatory and non-tumorous lesion.[1]It is a structural disorder of the mammary glands due to different degrees of hyperplasia and subinvolution of the mammary parenchy...Hyperplasia of the mammary glands(HMG)is a noninflammatory and non-tumorous lesion.[1]It is a structural disorder of the mammary glands due to different degrees of hyperplasia and subinvolution of the mammary parenchyma and stroma.In the literature,HMG is also called mastopathy,fibroadenosis,fibrocystic breast disease,mastalgia,fibrocystic change,benign mammary dysplasia,or sclerosing adenosis.展开更多
Ductal carcinoma in situ(DCIS),also known as intraductal carcinoma,is an in situ carcinoma limited to the mammary ducts.The gold-standard screening,diagnostic,and treatment options have long been controversial.The Chi...Ductal carcinoma in situ(DCIS),also known as intraductal carcinoma,is an in situ carcinoma limited to the mammary ducts.The gold-standard screening,diagnostic,and treatment options have long been controversial.The Chinese Society of Breast Surgery(CSBrS)has re-evaluated the quality of the clinical study evidence on DCIS.In order to standardize the diagnosis and treatment of DCIS and provide a reference for Chinese breast surgeons,the CSBrS has used the Grading of Recommendations Assessment,Development,and Evaluation handbook while referring to its feasibility in the actual clinical practice of Chinese breast surgeons to develop the CSBrS Clinical Practice Guideline for the Diagnosis and Treatment of Ductal Carcinoma In Situ(2021).展开更多
文摘Hyperplasia of the mammary glands(HMG)is a noninflammatory and non-tumorous lesion.[1]It is a structural disorder of the mammary glands due to different degrees of hyperplasia and subinvolution of the mammary parenchyma and stroma.In the literature,HMG is also called mastopathy,fibroadenosis,fibrocystic breast disease,mastalgia,fibrocystic change,benign mammary dysplasia,or sclerosing adenosis.
文摘Ductal carcinoma in situ(DCIS),also known as intraductal carcinoma,is an in situ carcinoma limited to the mammary ducts.The gold-standard screening,diagnostic,and treatment options have long been controversial.The Chinese Society of Breast Surgery(CSBrS)has re-evaluated the quality of the clinical study evidence on DCIS.In order to standardize the diagnosis and treatment of DCIS and provide a reference for Chinese breast surgeons,the CSBrS has used the Grading of Recommendations Assessment,Development,and Evaluation handbook while referring to its feasibility in the actual clinical practice of Chinese breast surgeons to develop the CSBrS Clinical Practice Guideline for the Diagnosis and Treatment of Ductal Carcinoma In Situ(2021).
